Seagen announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer. These late-breaking data were presented in an oral session at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer on July 2 in Barcelona, Spain. At a median duration of follow-up of 20.7 months, results of the MOUNTAINEER trial showed a 38.1% confirmed objective response rate per blinded independent central review in the HER2-positive patients who were assigned to receive tucatinib in combination with trastuzumab. In these patients, the median duration of response per BICR was 12.4 months. Median progression-free survival per BICR was 8.2 months, and median overall survival was 24.1 months. At study entry, 64.3% and 70.2% of these patients had liver or lung metastases, respectively, and had received a median of 3.0 prior lines of systemic therapy. In a cohort of patients who received tucatinib monotherapy, the ORR per BICR by 12 weeks was 3.3% and the disease control rate was 80.0%. Participants who did not respond to tucatinib monotherapy by 12 weeks or progressed at any time had the option to receive the combination of tucatinib and trastuzumab. AEs leading to discontinuation of any treatment occurred in 5.8% of patients. No deaths due to AEs were reported. Data from this trial will form the basis of a planned supplemental New Drug Application to the U.S. Food and Drug Administration under the Accelerated Approval Program. Merck, known as MSD outside the U.S. and Canada, has exclusive rights to commercialize TUKYSA in regions outside of the U.S., Canada and Europe and plans to discuss these results with certain global health authorities.

Seagen (SGEN) announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer, or mCRC. These late-breaking data were presented in an oral session at the European Society for Medical Oncology, or ESMO, World Congress on Gastrointestinal Cancer on July 2 in Barcelona, Spain. At a median duration of follow-up of 20.7 months, results of the MOUNTAINEER trial showed a 38.1% confirmed objective response rate, or cORR, per blinded independent central review in the HER2-positive patients who were assigned to receive tucatinib in combination with trastuzumab. In these patients, the median duration of response, or DoR, per BICR was 12.4 months. Median progression-free survival per BICR was 8.2 months and median overall survival was 24.1 months. At study entry, 64.3% and 70.2% of these patients had liver or lung metastases, respectively, and had received a median of 3.0 prior lines of systemic therapy. In a cohort of patients who received tucatinib monotherapy, the ORR per BICR by 12 weeks was 3.3% and the disease control rate was 80.0%. Participants who did not respond to tucatinib monotherapy by 12 weeks or progressed at any time had the option to receive the combination of tucatinib and trastuzumab. Data from this trial will form the basis of a planned supplemental New Drug Application to the U.S. Food and Drug Administration under the Accelerated Approval Program. Merck (MRK) has exclusive rights to commercialize TUKYSA in regions outside of the U.S., Canada and Europe and plans to discuss these results with certain global health authorities. "This study has shown the benefits of dual-HER2 inhibition with tucatinib and trastuzumab in patients with HER2-positive metastatic colorectal cancer, including many whose cancer had spread to the liver or lungs before joining the trial. We believe this chemotherapy-free combination may play an important role in addressing the unmet needs of patients with this disease," said Roger Dansey, M.D., interim CEO and Chief Medical Officer, Seagen.

Trump Media & Technology Group issued the following statement: "TMTG is expanding and enhancing Truth Social, with a major update to the platform scheduled for next week. TMTG will continue cooperating fully with inquiries into our planned merger and will comply with subpoenas we've recently received, none of which were directed at the company's Chairman or CEO."

In a regulatory filing, Macerich president Edward Coppola disclosed the purchase of 60,000 common shares of the company on June 30 at a price of $8.75 per share.

MAK Capital One changed its filing status to active from passive and intends to engage directly with Yatra.

Northrop Grumman was awarded a $337.94M cost-plus-fixed-fee, firm-fixed-price and cost reimbursable indefinite-delivery/indefinite-quantity contract. This contract provides researching alternatives, investigating and documenting new capabilities and anomalies related to H-1 avionics and weapons; and the development, integration, verification, validation, and testing of H-1 Integrated Avionics Systems, as well as identifies maintenance capabilities, upgrading and/or updating test equipment and other support equipment required to support the systems. Work is expected to be completed in June 2027. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to Defense Federal Acquisition Regulation 6.302-1. The Naval Air Warfare Center Weapons Division is the contracting activity.

On June 30, AT&T appointed Debra Dial to the position of Senior Vice President - Chief Accounting Officer and Controller, and Dial assumed the responsibilities of principal accounting officer. Dial has served in various positions with the company for 25 years, including as Senior Vice President - Controller for the last six years. The designation as the principal accounting officer recognizes her responsibilities as Chief Accounting Officer and conforms to prevalent industry practice. Pascal Desroches, the company's Senior Executive Vice President and CFO, acted as the company's principal accounting officer prior to Dial's appointment.

The U.S. FDA approved Sanofi's licensure request for vaccine approval for the upcoming 2022-2023 flu season, including: Fluzone High-Dose Quadrivalent (Influenza Vaccine), Flublok Quadrivalent (Influenza Vaccine) and Fluzone Quadrivalent (Influenza Vaccine). This approval comes on the heels of the CDC's Advisory Committee on Immunization Practices preferential recommendation for adults 65+ including Fluzone High-Dose Quadrivalent and Flublok Quadrivalent. Following this licensure, Sanofi will begin to ship their vaccines helping to ensure more people, including some of our most vulnerable population of 65 years and older, will be immunized with the vaccine best suited for their needs as recommended by the ACIP.